QuidelOrtho Corporation/$QDEL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
- Ticker
- $QDEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6,500
- Headquarters
- San Diego, United States
- Website
- www.quidelortho.com
QDEL Metrics
BasicAdvanced
$737M
-
-$5.40
0.80
-
Price and volume
Market cap
$737M
Beta
0.8
52-week high
$35.58
52-week low
$9.92
Average daily volume
2.4M
Financial strength
Current ratio
1.355
Quick ratio
0.621
Long term debt to equity
1.485
Total debt to equity
1.74
Interest coverage (TTM)
0.02%
Profitability
EBITDA (TTM)
462.6
Gross margin (TTM)
44.50%
Net profit margin (TTM)
-14.24%
Operating margin (TTM)
0.03%
Effective tax rate (TTM)
-9.88%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
0.01%
Return on equity (TTM)
-19.29%
Valuation
Price to revenue (TTM)
0.283
Price to book
0.41
Price to tangible book (TTM)
-0.88
Price to free cash flow (TTM)
-6.267
Free cash flow yield (TTM)
-15.96%
Free cash flow per share (TTM)
-1.714
Growth
Revenue change (TTM)
-4.47%
Earnings per share change (TTM)
-69.02%
3-year revenue growth (CAGR)
-6.00%
10-year revenue growth (CAGR)
29.93%
3-year earnings per share growth (CAGR)
201.17%
10-year earnings per share growth (CAGR)
30.67%
What the Analysts think about QDEL
Analyst ratings (Buy, Hold, Sell) for QuidelOrtho Corporation stock.
Analyst projections of the future price of QuidelOrtho Corporation stock.
Bulls say / Bears say
Core Labs and immunohematology are still growing outside China: in Q3, they rose 4% and 3% respectively in constant currency. Excluding China, respiratory and the donor-screening wind-down, total revenue grew 3%, pointing to resilience beneath the weak headline result. (QuidelOrtho, The Motley Fool)
The new restructuring programme is expected to deliver more than $80 million in annual savings in 2027. If achieved, that could strengthen margins and cash generation as the company manages current market pressures. (QuidelOrtho)
New products offer a possible growth engine: QuidelOrtho is expanding its VITROS 450 launch internationally and building placements for its NULEXA point-of-care molecular platform. Management says early customer engagement with NULEXA is encouraging and sees scope to expand its test menu. (The Motley Fool)
China is a sharp and persistent headwind: Q3 revenue fell 45% year on year as customers reduced orders amid pricing changes and destocking. Management expects more destocking through 2026 and further pricing pressure in 2027. (The Motley Fool)
Weak respiratory demand is dragging on Point of Care: revenue fell 27% in Q3, including a 39% drop in respiratory sales. The unpredictable season makes a near-term rebound uncertain. (QuidelOrtho, The Motley Fool)
High debt and weak cash conversion leave little room for setbacks: net debt was about $2.8 billion and leverage was 4.5 times adjusted EBITDA, while Q3 free cash flow was nearly flat. Lower earnings or delays in savings could make deleveraging harder. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
QDEL Financial Performance
Revenues and expenses
QDEL Earnings Performance
Company profitability
Upcoming events
No upcoming events
QDEL News
AllArticlesVideos
Funds containing QDEL
Fund name | Fund size | $QDEL weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.07% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.07% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.07% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.04% |
iShares S&P SmallCap 600$IDP6 | $2.5B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

